Norlin JM, et al. - Biologically naïve individuals with psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and EuroQol (EQ)-5D outcomes prior to (maximum 6 months) and following (3–12 months) switch to biologics during registration in the Swedish National Registry for Systemic Treatment of Psoriasis (PsoReg) were involved (n = 515) in order to investigate, in a real-world setting, that what factors were related to higher levels of treatment response to biologics and the health-related quality of life gains correlated with various response levels in clinical practice. High PASI percentage response was related to higher PASI prior to the switch and lower BMI. Within all responder groups, improvement in DLQI and EQ-5D was seen. The extent of improvements in DLQI varied among responder groups. In conclusion, PASI percentage variation is principally reliant on absolute PASI prior to the switch. Individuals in clinical practice deficit "baseline" PASI values since they may change directly from one treatment to another or stay fortunately treated for a longer time period. Moreover, for guidance in treatment or for follow-up in clinical practice, treatment goals like PASI 90 are therefore not apt.